Suzhou Medilink Therapeutics Ltd.
Industry
- Pharmaceuticals
- Biotechnology
- Large Molecule
- Antibodies
- Large Molecule
Latest on Suzhou Medilink Therapeutics Ltd.
Shanghai Henlius Biotech is trying to play a David versus Goliath game of catch-up with Pfizer, in pursuit of the commercialization of the world’s first PD-L1-targeting antibody-drug conjugate (ADC).
Taiho Pharmaceuticals said on 17 March that it will spend $400m up front and up to $740m in milestone payments to expand its cancer drug development pipeline through the acquisition of antibody-drug c
Who: Roche and Oxford BioTherapeutics What: The Swiss major has entered into a multi-year collaboration with OBT to develop first-in-class antibody-based therapeutics for the treatment of cancer.
Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Regenxbio Calls On Nippon Shinyaku To